ERBB2 and breast carcinoma: Phase II Randomized Trial of Combination Therapy of Paclitaxel and Bevacizumab Versus Paclitaxel, Capecitabine and Bevacizumab as First‐Line Treatment for Locally Recurrent or Metastatic Breast Cancer Patients with HER2/Neu Negative Tumor (ATX‐study)